# Brian Gallagher

> Brian Gallagher is a Series A investor at Abingworth backing Therapeutics and Biotechnology. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Abingworth](https://shizune.co/investors/profile/abingworth-management)
- Location: Cambridge, United States
- Total investments: 8
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/pub/brian-gallagher-jr/4/163/ba7
- X (Twitter): http://twitter.com/bmgallagherjr
- Website: https://x.com/bmgallagherjr

Brian Gallagher is a Series A investor at Abingworth in Cambridge focused on Therapeutics and Biotechnology. Brian Gallagher - Partner @ Abingworth

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 25% |
| Biotechnology | 2 | 25% |
| Medical | 1 | 13% |
| Genetics | 1 | 13% |
| Wellness | 1 | 13% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 13% |
| Series B | 1 | 13% |
| Series D | 1 | 13% |
| Series E | 1 | 13% |
| Series F | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Constellation Pharmaceuticals | Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $100M | Series F | Apr 09, 2018 |  |
| Aileron Therapeutics | Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $33M | Series E | Oct 29, 2014 |  |
| Aileron Therapeutics | Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $30M | Series E | Nov 18, 2013 |  |
| Aileron Therapeutics | Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $12M | Series D | Jan 14, 2013 |  |
| River Vision Development | River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York. | $17M | Series A | Dec 12, 2012 |  |
| Constellation Pharmaceuticals | Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $15M | Series B | Jun 06, 2011 |  |
| Constellation Pharmaceuticals | Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $22.3M | Series B | Jun 07, 2010 |  |
| Aileron Therapeutics | Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $40M | Series D | Jun 11, 2009 |  |

8 of 8 investments shown.

## Co-investors
- [Apple Tree Partners](https://shizune.co/investors/profile/apple-tree-partners) — VC Fund, 4 deals together
- [Excel Venture Management](https://shizune.co/investors/profile/excel-venture-management) — VC Fund, 4 deals together
- [Lilly Ventures](https://shizune.co/investors/profile/lilly-ventures) — VC Fund, 4 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 4 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 4 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 3 deals together

## About Abingworth

VC Fund · London, United Kingdom

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.

5 contacts available at Abingworth.

| Name | Title | Profile |
| --- | --- | --- |
| Brian Gallagher | Partner | https://shizune.co/investors/profile/brian-gallagher |
| John Shields | Advisor, Science and Technology | https://shizune.co/investors/profile/john-shields |
| Quentin Lloyd-Harris | Partner | https://shizune.co/investors/profile/genghis-lloyd-harris |
| Alex Asquith | General Counsel and Chief Financial Officer | https://shizune.co/investors/profile/alex-asquith |
| Andrew Sinclair | Partner & Portfolio Manager | https://shizune.co/investors/profile/andrew-sinclair |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Brian Gallagher invest in?

Brian Gallagher invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co